Document is current
Any future updates will be listed below
-
Authors
Kong, Weikaixin https://orcid.org/0000-0002-1070-7136
He, Liye https://orcid.org/0000-0002-6632-2112
Zhu, Jie
Brück, Oscar
Porkka, Kimmo
Heckman, Caroline A. https://orcid.org/0000-0002-4324-8706
Zhu, Sujie https://orcid.org/0000-0001-6488-9644
Aittokallio, Tero https://orcid.org/0000-0002-0886-9769
-
Funding
Funding for this research was provided by:
Academy of Finland (326238, 340141, 345803, 344698)
Kreftforeningen (216104)
Syöpäjärjestöt (NA)
- License Information
-
More Information
Article History
Received: 4 February 2022
Revised: 16 July 2022
Accepted: 20 July 2022
First Online: 9 August 2022
Competing interests
: KP: research funding from BMS/Celgene, Incyte, Pfizer, and Novartis, unrelated to this study. OB: consultancy from Novartis, Amgen, and Sanofi, outside the submitted work. CH: Research funding from BMS/Celgene, Kronos Bio, Novartis, Oncopeptides, Orion Pharma, and the IMI2 projects HARMONY and HARMONY PLUS, unrelated to this study. All the other authors declare no potential competing interests.
